Concerns over expansion of fast track surgery
October 28, 2003Doctors and health unions have expressed their concerns about the effect of new fast track surgery centres on the rest …
GlaxoSmithKline slashes AIDS drug prices
October 28, 2003Sales and Marketing
GlaxoSmithKline has cut prices of its HIV/AIDS drugs for developing countries by nearly half following intense pressure from campaigners and …
International performance keeps BMS afloat
October 28, 2003Sales and Marketing
International sales of several key drugs helped Bristol-Myers Squibb to minimise the effects of continued US generic competition in the …
Government proposes ‘clinical exceptions’ to A&E targets
October 28, 2003The Government is to modify one of its key waiting times targets after sustained protests about its inability to reflect …
Money Syner buy-out to create UK’s biggest healthcare agency
October 28, 2003Global healthcare communications agency Euro RSCG Life has acquired Money Syner Communications to create what it says will be the …
Pfizer spots potential of Organon atypical antipsychotic
October 28, 2003Pfizer is to co-develop and promote a promising new atypical antipsychotic discovered by Dutch pharma company Organon.Under the terms of …
Swiss pharma companies beat expecations
October 28, 2003Switzerland's number one pharmaceutical company Novartis has reported a sharp rise in sales in the first nine months of the …
Atypical anti-psychotics to get diabetes warning in US
October 28, 2003All atypical anti-psychotic drugs are to carry warnings on their US labels about potentially fatal hyperglycaemia side-effects and increased risk …
Job cuts at Merck
October 28, 2003US pharma giant Merck is to make 4,400 redundancies in an effort to stem falling profits, following a 7% drop …
Novartis Cox-II contender approved in UK
October 28, 2003A new rival to blockbuster Cox-II inhibitor drugs from Pfizer and Merck Sharp & Dohme has been approved in the …
Restructure unveiled as Pfizer takes merger hit
October 28, 2003Pfizer has unveiled a restructuring of its business to maximise its R&D and marketing might following the acquisition of Pharmacia …
New company to capitalise on industry M&A activity
October 28, 2003A new private European pharma company has been launched that will exploit products made available through the spate of industry …
AstraZeneca targets Canadian parallel imports
October 28, 2003AstraZeneca has become the second major pharma company to limit sales of drugs to Canada in a bid to curb …
New guidelines for industry ‘disease awareness’ campaigns
October 28, 2003Pharmaceutical industry 'disease awareness campaigns' aimed at UK consumers are to be governed by new guidelines to formalise the practice …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
